Search results for "Substance use disorder"
Q&A: DEA requires addiction training for all prescribers
The Drug Enforcement Administration is requiring eight hours of training related to substance use disorder treatment, sending clinicians scurrying to their continuing education providers for help.
https://immattersacp.org/archives/2023/05/dea-requires-addiction-training-for-all-prescribers.htm
1 May 2023
Illicitly manufactured fentanyls involved in increasing number of U.S. overdose deaths
From July 2019 to December 2020, sharp increases were seen in deaths involving illicitly manufactured fentanyls in midwestern (33.1%), southern (64.7%), and western (93.9%) jurisdictions, federal data indicate.
https://immattersacp.org/weekly/archives/2021/12/21/4.htm
21 Dec 2021
Guidance offered for treating patients exposed to xylazine
The animal sedative is now commonly found in illegally manufactured fentanyl and may pose even greater risks than that drug, according to authors of a recent review.
https://immattersacp.org/weekly/archives/2023/10/10/1.htm
10 Oct 2023
Point-of-care HCV test, new Alzheimer's drug approved
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/09/point-of-care-hcv-test-new-alzheimers-drug-approved.htm
1 Sep 2024
Drug screens early during treatment for OUD predict risk of return to opioid use
Patients whose urine drug screens in the three weeks after beginning treatment for opioid use disorder (OUD) were negative for opioids had a 13% risk of returning to opioid use compared with 85% for those with three weeks of opioid-positive or missing results.
https://immattersacp.org/weekly/archives/2023/10/10/2.htm
10 Oct 2023
Making strides to stamp out HCV
While there's a goal of eliminating viral hepatitis globally by 2030, reports indicate a disproportionately high rate of infection and death in the United States among medically underserved populations.
https://immattersacp.org/archives/2024/05/making-strides-to-stamp-out-hcv.htm
1 May 2024
ACP resources can help fulfill new DEA training requirement on substance use disorders
Starting June 27, 2023, the Drug Enforcement Administration (DEA) will require registered physicians to provide a one-time attestation that they have completed eight hours of training, and ACP's education resources can help.
https://immattersacp.org/weekly/archives/2023/04/11/5.htm
11 Apr 2023
Stories to change clinicians' views of substance use
A randomized clinical trial looked at the effects of a visual campaign and a narrative vignette on stigmas surrounding opioid use disorder.
https://immattersacp.org/archives/2022/06/stories-to-change-clinicians-views-of-substance-use.htm
1 Jun 2022
Racial disparities seen in U.S. drug overdose deaths in first year of pandemic
An analysis of CDC data found that while overall U.S. drug overdose deaths increased by 30% from 2019 to 2020, rates increased 44% among non-Hispanic Black and 39% among non-Hispanic American Indian or Alaska Native persons versus 22% in White persons.
https://immattersacp.org/weekly/archives/2022/07/26/2.htm
26 Jul 2022
Big barrier to buprenorphine removed
The U.S. government no longer requires an X waiver to treat patients with buprenorphine for opioid use disorder.
https://immattersacp.org/archives/2023/03/big-barrier-to-buprenorphine-removed.htm
1 Mar 2023